Stanford



Wubing Zhang

Postdoctoral Scholar, Stem Cell Biology and Regenerative Medicine

Curriculum Vitae available Online

Bio

PROFESSIONAL EDUCATION

- Doctor of Philosophy, Tongji University (2022)
- Bachelor of Science, Harbin Medical University (2017)
- Ph.D., Tongji University, Shanghai, China , Bioinformatics (2022)
- B.S., Harbin Medical University, Harbin, China , Bioinformatics (2017)

STANFORD ADVISORS

- Aaron Newman, Postdoctoral Faculty Sponsor
- Aaron Newman, Postdoctoral Research Mentor

LINKS

- Google Scholar: https://scholar.google.co.uk/citations?user=RDLA3YQAAAAJ&hl=en
- Github: https://github.com/WubingZhang
- Twitter: https://twitter.com/Wubing44589261
- linkedin: https://cn.linkedin.com/in/wubing-zhang-2168a0208

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

I'm interested in developing innovative methods and integrating multi-omics data to understand tumor-immune regulation and identify potential targets for cancer therapy.

Publications

PUBLICATIONS

- **Non-invasive profiling of the tumour microenvironment with spatial ecotypes.** *Nature*
  Zhang, W., Brown, E. L., Usmani, A., Earland, N., Kang, M., Olelewe, C., Viswanathan, A., Chauhan, P. S., Steen, C. B., Jeon, H. S., Avagyan, S., Alahi, I., Semenkovich, et al
  2026
- **Liquid biopsy profiling of the tumor microenvironment to determine response to immunotherapy regimens across solid tumors.**
  Brown, E. L., Zhang, W., Usmani, A., Earland, N., Hashmi, A., Olelewe, C., Viswanathan, A., Chauhan, P. S., Kang, M., Steen, C. B., Jeon, H., Avagyan, S., Alahi, et al
  AMER ASSOC CANCER RESEARCH.2026: 94

- **Improved reconstruction of single-cell developmental potential with CytoTRACE 2.** *Nature methods*
  Kang, M., Gulati, G. S., Brown, E. L., Qi, Z., Avagyan, S., Armenteros, J. J., Gleyzer, R., Zhang, W., Steen, C. B., D'Silva, J. P., Schwab, J., Clarke, M. F., Chaudhuri, et al
  2025
- **Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells.** *Immunity*
  Luo, C., Zhang, R., Guo, R., Wu, L., Xue, T., He, Y., Jin, Y., Zhao, Y., Zhang, Z., Zhang, P., Ye, S., Li, X., Li, et al
  2025
- **CD4 T cells and toxicity from immune checkpoint blockade.** *Immunological reviews*
  Earland, N., Zhang, W., Usmani, A., Nene, A., Bacchiocchi, A., Chen, D. Y., Sznol, M., Halaban, R., Chaudhuri, A. A., Newman, A. M.
  2023
- **High-resolution alignment of single-cell and spatial transcriptomes with CytoSPACE.** *Nature biotechnology*
  Vahid, M. R., Brown, E. L., Steen, C. B., Zhang, W., Jeon, H. S., Kang, M., Gentles, A. J., Newman, A. M.
  2023
- **Cancer Cell Resistance to IFNg Can Occur via Enhanced Double-Strand Break Repair Pathway Activity** *CANCER IMMUNOLOGY RESEARCH*
  Han, T., Wang, X., Shi, S., Zhang, W., Wang, J., Wu, Q., Li, Z., Fu, J., Zheng, R., Zhang, J., Tang, Q., Zhang, P., Wang, et al
  2023; 11 (3): 381-398
- **Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-secreted Cytokines.** *Cancer discovery*
  Ito, Y., Pan, D., Zhang, W., Zhang, X., Juan, T. Y., Pyrdol, J. W., Kyrysyuk, O., Doench, J. G., Liu, X. S., Wucherpfennig, K. W.
  2023
- **Machine learning on syngeneic mouse tumor profiles to model clinical immunotherapy response.** *Science advances*
  Zeng, Z., Gu, S. S., Wong, C. J., Yang, L., Ouardaoui, N., Li, D., Zhang, W., Brown, M., Liu, X. S.
  2022; 8 (41): eabm8564
- **Hippo signaling pathway regulates cancer cell-intrinsic MHC-II expression.** *Cancer immunology research*
  Zeng, Z., Gu, S. S., Ouardaoui, N., Tymm, C., Yang, L., Wong, C. J., Li, D., Zhang, W., Wang, X., Weirather, J. L., Rodig, S. J., Hodi, F. S., Brown, et al
  2022
- **Machine Learning Modeling of Protein-intrinsic Features Predicts Tractability of Targeted Protein Degradation** *GENOMICS PROTEOMICS & BIOINFORMATICS*
  Zhang, W., Burman, S., Chen, J., Donovan, K. A., Cao, Y., Shu, C., Zhang, B., Zeng, Z., Gu, S., Zhang, Y., Li, D., Fischer, E. S., Tokheim, et al
  2022; 20 (5): 882-898
- **TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response** *NUCLEIC ACIDS RESEARCH*
  Zeng, Z., Wong, C. J., Yang, L., Ouardaoui, N., Li, D., Zhang, W., Gu, S., Zhang, Y., Liu, Y., Wang, X., Fu, J., Zhou, L., Zhang, et al
  2022; 50 (D1): D1391-D1397
- **Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade** *CANCER DISCOVERY*
  Gu, S., Zhang, W., Wang, X., Jiang, P., Traugh, N., Li, Z., Meyer, C., Stewig, B., Xie, Y., Bu, X., Manos, M. P., Font-Tello, A., Gjini, et al
  2021; 11 (6): 1524-1541
- **Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors** *CLINICAL CANCER RESEARCH*
  Shi, S., Gu, S., Han, T., Zhang, W., Huang, L., Li, Z., Pan, D., Fu, J., Ge, J., Brown, M., Zhang, P., Jiang, P., Wucherpfennig, et al
  2020; 26 (22): 5990-6002
- **Clonal tracing reveals diverse patterns of response to immune checkpoint blockade** *GENOME BIOLOGY*
  Gu, S., Wang, X., Hu, X., Jiang, P., Li, Z., Traugh, N., Bu, X., Tang, Q., Wang, C., Zeng, Z., Fu, J., Meyer, C., Zhang, et al
  2020; 21 (1): 263
- **Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute** *NATURE PROTOCOLS*
  Wang, B., Wang, M., Zhang, W., Xiao, T., Chen, C., Wu, A., Wu, F., Traugh, N., Wang, X., Li, Z., Mei, S., Cui, Y., Shi, et al
  2019; 14 (3): 756-780

- **IGSA: Individual Gene Sets Analysis, including Enrichment and Clustering** *PLOS ONE*
  Wu, L., Chen, X., Zhang, D., Zhang, W., Liu, L., Ma, H., Yang, J., Xie, H., Liu, B., Jin, Q.
  2016; 11 (10): e0164542

PRESENTATIONS

- Machine learning modeling of protein-intrinsic features predicts tractability of targeted protein degradation - Dana-Farber Cancer Institute Targeted Protein Degradation Seminar Series
- Depmap